CTLA4 and neoplasm: The combination of immune checkpoint blockade with immunotherapies such as CTLA-4, PD-1, and PD-L1 inhibitors is a promising approach to treat a variety of malignancies, and an activated tumor immune microenvironment is correlated with good outcomes of immune checkpoint inhibitor treatment [38, 39].